Caution About Using Gliptins in Heart Failure Patients

July 2015

See updated information from the FDA concerning heart failure risk with saxagliptin and alogliptin

You'll see new warnings about a possible increased risk of heart failure with saxagliptin (Onglyza, etc) and alogliptin (Nesina, etc).

So far, saxagliptin has the strongest evidence. There's one heart failure hospitalization for every 143 patients treated with saxagliptin over 2 years.

Alogliptin seems less likely to be linked to heart failure...sitagliptin (Januvia) doesn't seem to be a problem...and it's too early to say if linagliptin (Tradjenta) increases risk.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote